globenewswire.com · 9 jul

IN8bio Announces Publication in The Journal of Clinical Oncology Demonstrating DeltEx™ DRI Doubles Progression-Free Survival in Newly Diagnosed Glioblastoma

First peer-reviewed publication of chemotherapy-resistant gamma-delta T cells (DeltEx Drug Resistant Immunotherapy or DRI) clinical results in newly diagnosed glioblastoma Repeat-dose patients achieved median progression-free survival (mPFS) of 16.1 months, more than double the ~6.9-month standard of care benchmark, with no dose-limiting toxicities (DLTs) NEW YORK, July 09, 2026 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical company developing innovative gamma-delta (γδ) T cell therapies and T cell engagers for cancer and autoimmune diseases, today announced the publication of peer-reviewed clinical data from its Phase 1 trial of INB-200 in The Journal of Clinical Oncology (JCO), one of the most prestigious oncology journals. The publication, titled: “ Intracranial injection of ex vivo expanded and activated gamma-delta T cells engineered with a MGMT-expressing lentivector in patients with primary glioblastoma ,” reports results from the first-in-human study of an autologous, genetically modified γδ T cell therapy.

zacks.com · 2 jul

Darden Stock Outlook Centers on Growth Brands and Cost Risks

DRI enters fiscal 2027 with growth from LongHorn, digital initiatives and new restaurants, while inflation and cautious spending test margins.

zacks.com · 2 jul

Is DRI Stock a Buy Now After Earnings Growth and Valuation Reset

Darden combines earnings growth, cash returns and a lower valuation multiple, but estimate cuts and inflation keep investors weighing the stock's outlook.

zacks.com · 2 jul

Darden Stock Trends Show Digital Gains and Margin Pressure

DRI is balancing digital growth, brand diversification and value-focused pricing as inflation and consumer spending trends shape its margin outlook.

seekingalpha.com · 1 jul

Dividend Announcements: June 20-26, 2026

In this article series, I summarize dividend announcements of the past week. Thirteen companies in my database (including 7 banks) announced dividend increases. JPMorgan Chase stands out with a 10% dividend hike, an A+ safety grade, and a new $50B buyback, and trades only 3.35% above fair value. Matson is the week's high-quality non-bank, boasting a 7.34 quality score, 9.4 safety score, and a conservative 10% payout ratio.

marketbeat.com · 29 jun

New Stock Price Highs Are on the Menu for Darden Restaurants

Darden Restaurants' NYSE: DRI stock price is on track to hit new highs because its high-quality business is outperforming peers, growing across brands, generating ample cash flows, and sustaining a robust capital return program. The capital return program is a significant factor in 2026, with investors reducing exposure to high-risk tech stocks in favor of safer havens.

benzinga.com · 26 jun

Darden Analysts Boost Their Forecasts After Q4 Results

Darden Restaurants, Inc. (NYSE:DRI) reported mixed financial results for the fourth quarter on Thursday.

zacks.com · 26 jun

Darden Q4 Earnings Call Flags Balanced Growth and Pricing Discipline

DRI's fiscal fourth-quarter call highlights balanced growth, pricing discipline and steady demand, with LongHorn gaining share and fiscal 2027 guardrails in focus.